September 29, 2003
BIOLASE Trading Symbol Reverts Back to BLTI
BIOLASE Technology, Inc. (NASDAQ:BLTIE) , today announced that it received notification from the Nasdaq Stock Market that the Company's trading symbol will be changed to BLTI effective when business opens on Monday, September 22, 2003.
On September 17 the Company filed its quarterly report for the second quarter of 2003 as well as amended reports on Forms 10-K/A and 10-Q/A and is therefore current in its Nasdaq reporting requirements.
Nasdaq also notified the Company that the scheduled hearing before the Nasdaq Listing Qualifications Panel is now considered moot since the Company has evidenced compliance with the public reporting requirements and all other requirements necessary for continued listing on The Nasdaq National Market.
About BIOLASE
BIOLASE Technology, Inc. ( http://www.biolase.com/ ) is a medical technology company that designs, manufacturers and markets proprietary dental laser systems that allow dentists, oral surgeons and other specialists to perform a broad range of common dental procedures, including cosmetic applications. The company's products incorporate patented and patent pending technologies focused on reducing pain and improving clinical results. Its primary product, the Waterlase system, is the best selling dental laser system. The Waterlase system uses a patented combination of water and laser to precisely cut hard tissue, such as bone and teeth, and soft tissue, such as gums, with minimal or no damage to surrounding tissue. The company also offers the LaserSmile system, which uses a laser to perform soft tissue and cosmetic procedures, including tooth whitening. In May 2003, the company acquired the American Dental Laser product line, including the Diolase and Pulsemaster systems, which can be used for common soft tissue procedures.
Source: BIOLASE Technology, Inc.
September 29, 2003
PULPDENT RELEASES FIRST MOIST-BONDING RESIN
Pulpdent Corporation’s Embrace™ WetBond Seal-n-Shine™ is the first moist-bonding resin specifically designed for sealing, finishing, and polishing composite restorations. Formulated with advanced, hydrophilic Resin Acid-Integrating Network (R.A.I.N.), it bonds chemically and mechanically to teeth and composites, providing strong bonds.
Seal-n-Shine is a clear resin that penetrates and seals porosities and cracks within composites and seals margins. It provides a smooth, durable finish that eliminates the need for final finishing and polishing. Seal-n-Shine does not alter the occlusal anatomy of the tooth or discolor the restoration and contains no solvents. There is no need to mix or add solvents or other modifiers.
Providing quick finishing and polishing of composites, etched or abraded ceramic restorations and acrylic temporary crowns, Seal-n-Shine also repairs cracked teeth; seals non-carious or precarious lesions, enamel defects, and notches; and seals margins of indirect restorations cemented with resin cement. Seal-n-Shine can be cured using any curing light and, once cured, creates a marginal seal and is impervious to water.
Embrace Wet Bond Seal-n-Shine is available from dental dealers in a 6 mL bottle with a brush handle and 100 brush tips and is also available in 2 x 1.2 mL syringes with 40 flocked tips. There is a $5.00 manufacturer’s rebate in effect through March 31, 2004 with proof of purchase.
Pulpdent manufactures high-quality products for the dental profession, including adhesives, composites, sealants, cements, etching gels, calcium hydroxide products, endodontic specialties, and bonding accessories. For more information, call 800-343-4342 or visit www.pulpdent.com.
September 28, 2003
Gillette Selects Learn HealthSci Inc. to Train Sales Reps on New Power Toothbrush
The Gillette Company (NYSE: G), the leader in the $4.5 billion worldwide physical oral care market, has hired Learn HealthSci Inc. to create, produce, web-enable and track the results of a new sales rep multimedia training program for the introduction of the new Oral-B ProfessionalCare 7000 Series power toothbrush. The training program will be distributed to over 1000 selected retail sales reps within the United States and Canada through Learn HealthSci’s innovative Internet-based multimedia training platform.
September 24, 2003
CROSSTEX INTRODUCES THE ULTRA SENSITIVE MASK
Ultra Sensitive is completely void of inks, dyes, and chemicals. It has a white cellulose inner layer made specifically for sensitive skin. In addition, this layer will not lint, tear, or shred. The white, fluid resistant outer layer is made of a unique spun bond material for maximum protection. Fluid resistant masks resist body fluids and do not permit blood or other potentially infectious materials to pass through to reach the skin, nose, mouth, or other mucous membranes under normal conditions of use.
The Ultra Sensitive mask has a PFE of 99% @ 0.1 Microns. PFE, or Particle Filtration Efficiency, measures the filtration efficiency of a mask using nonliving, or nonviable particles that are fixed in size from 0.1 micron to 1 micron. The higher the PFE, the more protection the wearer has. The Ultra Sensitive provides a very high level of protection and easy breathability in addition to being designed for those with sensitive skin.
Ultra Sensitive masks are latex free, made in the U.S.A., and sold in boxes of 50. Crosstex offers a complete line of face masks for all levels of protection from the basic exam to the treatment of high-risk patients. For more information, or to request a sample, call 888-Crosstex.
September 24, 2003
CROSSTEX INTRODUCES ULTRA GAUZE™ SPONGES
Crosstex International is expanding its product line with the introduction of Ultra Gauze™ sponges, a general-use product using Nu Gauze® sponge material.
Ultra Gauze™ is manufactured using patented APEX® technology. This patented technology creates engineered fabrics that combine all the strengths of traditional materials with the most advanced manufacturing technology and processes. Using highly developed, state-of-the-art laser imaging techniques, new and innovative fabrics are created with unique textile-like properties. Along with the look, feel, strength, and durability of traditionally woven or knit fabrics, the materials produced through this three-dimensional process have added absorbency, are more versatile and cost-effective.
Ultra Gauze™, is made of this exclusive rayon/polyester formed non-woven material that provides almost 50% more absorbency than traditional sponges. The multipurpose, easy-to-use sponges are also extremely cost-effective as they are manufactured for numerous daily routine functions including, but not limited to, cleaning, prepping, and placement on incision/extraction sites. Ultra Gauze™ produces little or no lint and does not stick to surfaces. It is also superior in maintaining its shape and texture during use compared to traditional all gauze/exodontia sponges.
Like all Crosstex products, Ultra Gauze™ is the result of the Crosstex commitment to consistent quality product development. Ultra Gauze™ will help fill the void left by recently announced phase out of select wound care products by industry leader Johnson & Johnson® Wound Management, a division of Ethicon®, Inc.
Ultra Gauze™ general-use sponges are made in the U.S.A. and are available in 2” x 2”, 3” x 3” and 4” x 4”. Crosstex is celebrating its 50th year of providing the healthcare industry with innovative, high-quality infection control/single-use disposable products. For more information, or to request a sample, call 888-Crosstex.
September 10, 2003
Ergotron Announces the Formation of a New Company
We are very pleased to announce the formation of a new company, Ergotron Canada Corporation, effective July 1st, 2003. Ergotron Canada has been organized and structured to provide you with a world class range of products and level of customer care.
Our previous distributor, Bidinoff Marketing, has done an outstanding job of serving the Canadian market for 12 years with Ergotron products. They will continue to provide sales and administrative support through the transition of Ergotron Canada.
Ergotron, Inc. is a world leader in improving the human interface with computers by designing and manufacturing innovative and ergonomic computer hardware management solutions of the highest quality to meet specific customer needs. With headquarters in Minnesota, Ergotron has five subsidiaries in Europe and is represented in countries worldwide.
http://www.ergotron.ca/
September 5, 2003
Discus Dental releases New Fluoridex Daily Defense™ Twin-Pak
Today, dental care professionals have a choice when they prescribe the healing benefits of Discus Dental's Fluoridex Daily Defense™ 1.1% Neutral Sodium Fluoride Toothpaste. It's now available in a convenient Twin-Pak with two 2-oz tubes each as well as the standard 4 oz. tubes. The Twin Pak delivers all the patient-friendly features doctors depend on in the 4 oz. tube--stand-up design, flip-top cap, stylish packaging and Clean Mint flavor--but now in two smaller-size, travel-ready tubes.
Whether you prescribe the traditional 4 oz. tubes or the new Twin-Pak 2 oz. tubes, Fluoridex Daily Defense™ is the dental professional's #1 choice for the treatment of a number of caries active indications, including root caries, xerostomia-induced caries and recurrent caries. , Fluoridex Daily Defense™ is also is ideal for the prevention and treatment of orthodontic decalcification and tooth whitening sensitivity.
For more information, please call Discus Dental at (800) 422-9448 or visit our website at www.discusdental.com.
September 5, 2003
Kodak Changes Color of Cook-Waite Carbocaine 3%
Eastman Kodak Company announced today it will change the color of its Cook-Waite Carbocaine 3% local injectable dental anesthetic cans and cartridges, bringing the packaging in compliance with a color-coding system set by the American Dental Association (ADA) Seal of Acceptance Program.
Formerly, the color of Cook-Waite Carbocaine 3% anesthetic cans and cartridges was teal (blue-green). The new color is tan. The anesthetic will continue to carry the ADA Seal of Acceptance.
The rest of the Cook-Waite local injectable dental anesthetics line is already in compliance with the ADA guidelines.
The color-coding guidelines were established by the ADA Council on Scientific Affairs. They are intended to standardize dental anesthetic cartridges and make it easier for practitioners to ensure they are using the intended anesthetic.
Cook-Waite Carbocaine HCl 3% injection in the tan color scheme will begin shipping to dental supply dealers in the September timeframe. Dental practices will begin to receive it later in the fall.
For more information about Cook-Waite brand local injectable dental anesthetics, call 800-933-8031 or visit Kodak's Health Imaging Dental Products Group website at www.kodak.com/go/dental.
September 5, 2003
BriteSmile Expands U.S. Network
BriteSmile, a leading provider of state-of-the-art teeth whitening, today announced the company's move to expand its successful, dentist-run Spa model in the United States. BriteSmile plans to open an additional eight to ten new Spas in the next 18 months.
Leveraging BriteSmile's unique teeth whitening Spa model and the great success of its existing New York Spa on West 57th Street, BriteSmile will initiate its expansion with the opening of a new Spa in the heart of downtown New York's Soho shopping district. The Spa will be located at 131 Prince Street, between Wooster Street and West Broadway. The Soho Spa is expected to open by the end of the calendar year.
"We are very excited at our ability to expand our successful spa model and at having an exciting new dynamic location to offer our procedure and products through," said John Reed, BriteSmile CEO. "We look forward to opening our new Spa in Soho and continuing to provide the best in a professional teeth whitening spa experience."
Dedicated exclusively to the BriteSmile treatment, the Soho Spa will provide a luxurious and relaxing teeth whitening experience in an upscale spa- like setting. Customers can relax and watch TV during the convenient one hour treatment. Located in some of the country's premium shopping districts in major cities across the country, BriteSmile Spas provide a dentist-supervised treatment with the individual attention of a pampering Spa treatment.
BriteSmile (NASDAQ:BSML) has developed and manufactures the most advanced teeth whitening technology available, as well as manages state-of-the-art BriteSmile Professional Teeth Whitening Spas. BriteSmile Spas are currently operating in Beverly Hills, Irvine, Palo Alto, Walnut Creek and La Jolla, CA; Honolulu, HI; Houston, TX; Denver, CO; Boston, MA; Boca Raton, FL; Atlanta, GA; New York, NY; Chicago, IL; and, Phoenix, AZ. In addition to BriteSmile Spas, the Company has contracted with independent dentists to perform teeth whitening treatments at more than 4,500 Associated Spas. Of the BriteSmile Associated Spas, more than 1,300 are located outside of the United States. For more information about BriteSmile's teeth whitening treatment, call 800- BRITESMILE or visit the Company's Website at http://www.britesmile.com/ .
September 5, 2003
BIOLASE Receives SEC Guidance
BIOLASE Technology, Inc. (NASDAQ:BLTIE) , announced today that, based upon guidance from the Securities and Exchange Commission received on August 28, the Company will amend previously issued financial statements to account for timing differences in revenue recognition. Accordingly, prior-period financial statements will be adjusted to recognize revenue when payment was actually received rather than when products were shipped. While this will reduce revenue and earnings for prior periods, the Company expects the effect of these changes will be offset by a one-time positive impact on third quarter 2003 revenue and earnings, and that there will not be any impact thereafter, because BIOLASE has now modified the language in question in its purchase order forms to allow revenue recognition upon shipment.
The Company plans to file an amended Form 10-K for 2002, which will restate revenue for 2000-2002, and amended Form 10-Q's for the quarters ended March 31, 2002 through March 31, 2003.
Jeffrey W. Jones, BIOLASE President and CEO, stated, "We are simply glad to put this matter behind us and move on. The timing of the issue was unfortunate in that it has delayed our public offering. We will also incur heavier than normal professional fees, which we are estimating will be less than $500,000, in the third quarter as a result of our efforts to resolve this matter. However, this issue has not affected the economic fundamentals of our business. As soon as these changes to our filings are made, we intend to complete the registration process and our public offering as planned."
On August 7, 2003, BIOLASE announced that it would seek guidance from the SEC regarding the accounting effect of certain language in the Company's purchase order forms. Under a recent review of the Company's standard purchase orders, a technical question arose as to whether or not revenue should be recognized upon shipment, which has been the Company's historical practice, or when payment is received from customers.
The Company could not file its quarterly report on Form 10-Q for the quarter ended June 30, 2003 until the amended filings, if found to be necessary, could be made. Timely filing of reports is required by Nasdaq Marketplace Rule 4310(c)(14). As a result, following standard administrative procedures, the Company received a Nasdaq staff determination on August 22, 2003 that it may be subject to delisting from the Nasdaq Stock Market. The Company has requested a hearing before a Nasdaq Listing Qualification Panel to review the staff determination. The Company has prepared the amended filings and is submitting them to its independent accountants and therefore expects that, before the hearing is scheduled, the Company will have filed its quarterly report on Form 10-Q for the quarter ended June 30, 2003 and amended prior period reports and become current in its reporting obligations. The Company therefore expects that it will have met all Nasdaq requirements.
Until the restatements are completed, the financial information contained in the reports previously filed with the SEC for the previously stated periods should not be relied upon, including reports of the Company's independent accountants for these periods.